HIV Archives – Page 22 of 90 – Treatment Action Group

Fierce Activism from the Global Access to Medicines (A2M) Movement: Reflections on Recent Sucess

December 7, 2018
Chad Cipiti

By Bryn Gay, HCV Project Director, TAG Access to medicines (A2M) activists have become better coordinated, articulate, and adept in responding to pharmaceutical industry shenanigans that threaten access to affordable medicines since the establishment of harmonized global intellectual property (IP) …

Whose Intellect? Whose Property? A Blueprint for Bringing Down the Pharma IP House of Cards

December 7, 2018
Chad Cipiti

By JD Davids, TAGline Guest Editor and Suraj Madoori, U.S. and Global Health Policy Director, TAG As the Trump administration makes noise about the high price of pharmaceuticals while doubling down on its commitment to “protect the engine of American…

Treatment Action Group Generates Novel HIV Cure Research Resources with the Support of the Elizabeth Taylor AIDS Foundation and Macy’s Inc./“Thanks for Giving”

December 6, 2018
Chad Cipiti

Treatment Action Group has released a new report focusing on the ethically complex and potentially risky aspect of research aiming to develop a cure for HIV infection: the use of “analytical treatment interruptions” (ATIs) in clinical studies to investigate how HIV viral load rebounds, and whether experimental interventions can limit viral replication after antiretroviral therapy (ART) is interrupted.

About TAG: The Legacy and Future of Activism to Catalyze the End to HIV/AIDS, Tuberculosis, and Hepatitis C

December 6, 2018
Dorrit Walsh

This two-page brief explains TAG’s mission, gives information about TAG’s origins, describes how we work, and lists some of our many accomplishments since our founding in 1992.

2018 TAG Update

December 4, 2018
Chad Cipiti

I want to thank all of you for the support that enabled the successes TAG achieved this past year. Despite a challenging political climate and continued attacks against those living with or at risk of contracting HIV, tuberculosis (TB), or…

Treatment Action Group Statement on the Reported Birth of Twins with Edited CCR5 Genes

November 26, 2018
Chad Cipiti

Treatment Action Group (TAG) decries the claimed use of CRISPR technology to edit genes for the HIV co-receptor CCR5 in human embryos for implantation.

Story: Claims that “Gammora” Represents a Potential HIV Cure

November 20, 2018
Dorrit Walsh

October – November 2018 Examples of media coverage: HIV cure? Major breakthrough made in eradicating deadly virus: ‘Beyond our expectations’ – Daily Star, November 1, 2018 New drug could cure HIV/Aids – Uganda Daily Monitor, November 7, 2018 Maker of ‘potential HIV…

Community Recommendations for Clinical Research Involving Antiretroviral Treatment Interruptions in Adults

November 14, 2018
Chad Cipiti

Combination antiretroviral therapy (ART) is now recommended for all people with HIV. Suppression of HIV viral load to undetectable levels by ART greatly benefits individual health—causing lifespans for many people with HIV to approach those of comparable HIV-negative individuals—and eliminates the risk of most forms of HIV transmission.

Research Toward a Cure Trials Supplemental References Page

October 30, 2018
Chad Cipiti

Treatment Intensification/Early Treatment AAHIV/RV254: Antiretroviral therapy for acute HIV infection NCT00796263 Establish and characterize an acute HIV infection cohort in a high-risk population NCT00796146 (related observational study) References Wietgrefe SW, Anderson J, Duan L, et al. Initial productive and latent…

Right to Science Submission – October, 2018

October 16, 2018
Chad Cipiti

The right to enjoy the benefits of scientific progress and its applications is a fundamental human right and one of the central pillars of TAG's advocacy to promote TB research and access to its benefits. The right is enshrined in Article 27 of the Universal Declaration of Human Rights and further articulated in Article 15 of the International Covenant on Economic, Social, and Cultural Rights (ICESCR).